World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development

World Health Assembly 67: HAI intervention on access to essential medicines

World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors

Action on antimicrobial resistance: It’s about time (and we’re running out)

Tamiflu review shows desperate need for full clinical trials data transparency

Governments must ensure Big Pharma’s expansion in Africa doesn’t impede generics supply

New materials help assess medicines policies and interventions

A new (and improved) model to regulate pharmaceutical promotion

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

Bayer CEO's callous comments highlight failure of current biomedical innovation model

Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed

Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed

Regulation critical to clinical trials data transparency in Europe


When politicians go to the movies

True clinical trials transparency? Not quite, EFPIA.

Conference contemplations: ‘Pharmaceuticals and global health – inequalities and innovation in the 21st century’

Good week for access to affordable medicines

Despite concrete steps forward, the ENVI vote on clinical trials regulation falls short on transparency

Bracing for another delay – open innovation at the WHO?


EU Policy Opportunities in Biomedical Innovation and the Public Good

Statement on Medicines Patent Pool

Public Event on EU-MERCOSUR in Buenos Aires

Study provides recommendations on European Medicines Agency's communication on medicines

The Diagnosis of Childhood Bipolar Disease has led to Catastrophic Consequences

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

TRIPS-Plus IP demands from EU could halt South American trade deal

EU Mercosur Trade Negotiations in July

HAI Europe’s participation at the “Ad hoc meeting – Bilateral trade negotiations: State of Play”

Conflicts of interest at the European Medicines Agency (EMA) and the need for a review of staff regulations

Submission to the Consultative Expert Working Group (CEWG) on alternative financing